Jardiance(R) meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in phase III trial in adults with and without diabetes

Jardiance (empagliflozin) significantly reduced the risk of cardiovascular death or hospitalization for heart failure versus placebo in the EMPEROR-Reduced heart failure trial. The study evaluated adults with heart failure with reduced ejection fraction ... Biopharmaceuticals, Endocrinology Eli Lilly, Jardiance, empagliflozin, diabetes
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news